Drug intelligence / Profile preview

Tozal

Development stage: Unknown
Lead developer: Focus Laboratories
Administration: Oral

Overview

Tozal is a comprehensive nutritional supplement specifically formulated for the management of atrophic (dry) age-related macular degeneration (AMD). Its formulation is based on the Age-Related Eye Disease Study (AREDS) findings but is enhanced with additional nutrients including taurine, lutein, zeaxanthin, and omega-3 fatty acids (EPA and DHA). The supplement is designed to support macular health by providing antioxidant protection against oxidative stress and filtering harmful high-energy blue light. Clinical data from the TOZAL study demonstrated that the supplement can help stabilize or improve best-corrected visual acuity (BCVA) in patients with dry AMD by providing targeted nutritional support to the retina.

Brand names: Tozal
Other names: TOZAL formulation

Beyond the preview

Go deeper on Tozal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tozal.

Explore the full profile